Forearm Vascular Relaxation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to learn the effect of inherited differences on forearm blood flow responses to hormones and drugs
| Condition |
|---|
|
Healthy |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Determinants of Forearm Vascular Relaxation: Role of Genetic Polymorphisms |
| Estimated Enrollment: | 400 |
| Study Start Date: | May 2003 |
| Study Completion Date: | December 2006 |
| Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
Differences in at least 4 genes are believed to have an important effect on responses to hormones and drugs. For this study, healthy volunteers of normal body weight will be screened to find xxx individuals with the genes of interest. Very small doses of hormones and drugs will be given so that changes in forearm blood flow can be measured, while not causing effects throughout the body. A brachial artery line and venous line will be placed in the study arm so that blood samples may be withdrawn to compare amounts given into the artery and coming out of the vein after circulating through the arm. Forearm blood flow is determined by the rate of swelling of the arm after a blood pressure cuff is inflated (above venous and below arterial blood pressure). The hormones and drugs being studied include angiotensin I, angiotensin II, acetylcholine, sodium nitroprusside, enalaprilat, L-arginine, phenylephrine, endothelin-1, verapamil, and isoproterenol. This procedure will last 4-6 hours. The process will be repeated with the same participant over 2 weeks later.
Eligibility| Ages Eligible for Study: | 21 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Normal physical status without any medical interventions or agents which would alter the defined status of normal
Exclusion Criteria:
- Age less than 21 or greater than 45
- Unable to give informed consent
- BMI (Body Mass Index) less than 18 or greater than 25
- Clinically significant abnormal laboratory values
- Abnormal physical exam
- Abnormal EKG
- Pregnancy
- Smoking or drug usage (illicit or otherwise)
- Post-menopause
- Participation in another clinical trial in the past month
- Chronic Illness
Contacts and Locations| United States, Maryland | |
| National Institute on Aging (NIA), Harbor Hospital | |
| Baltimore, Maryland, United States, 21225 | |
| Principal Investigator: | Darrell R. Abernethy, MD, PhD | National Institute on Aging, Laboratory of Clinical Investigation |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00182923 History of Changes |
| Other Study ID Numbers: | AG0038 |
| Study First Received: | September 12, 2005 |
| Last Updated: | August 28, 2008 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute on Aging (NIA):
|
Blood pressure genetics |
ClinicalTrials.gov processed this record on May 23, 2013